HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

GW 610742

structure in first source

Also Known As:

GW-610742; GW610742

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Sulfur Compounds: 278
  - Thiazoles: 392
    - GW 610742: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - GW 610742: 3

Experts

1.	Ahn, Jong Hwa: 1 article (01/2016)
2.	Hwang, Jin-Yong: 1 article (01/2016)
3.	Hwang, Seok-Jae: 1 article (01/2016)
4.	Jeong, Young-Hoon: 1 article (01/2016)
5.	Jung, Myeong Hee: 1 article (01/2016)
6.	Kim, Jin Hyun: 1 article (01/2016)
7.	Koh, Jin-Sin: 1 article (01/2016)
8.	Kwak, Choong Hwan: 1 article (01/2016)
9.	Lee, Young Soo: 1 article (01/2016)
10.	Park, Jeong Rang: 1 article (01/2016)

Related Diseases

1.	Diabetic Nephropathies (Diabetic Nephropathy) 11/01/2012 - "This study investigated the efficacy of GW610742, a highly specific agonist for PPAR-δ, for the treatment of diabetic nephropathy. " 11/01/2012 - "PPAR-δ activation by GW610742 ameliorates albuminuria by preventing diabetes-induced nephrin loss and restoring podocyte integrity, implying that GW610742 may be a potential therapeutic agent for diabetic nephropathy."
2.	Albuminuria 11/01/2012 - "Diabetic albuminuria and renal injury markers, such as glomerular basement membrane thickening, decreased number of slit pores between podocyte foot processes, decreased nephrin expression, increased desmin expression and increased CCL2 expression, were significantly reversed through the treatment with GW610742. " 11/01/2012 - "PPAR-δ activation by GW610742 ameliorates albuminuria by preventing diabetes-induced nephrin loss and restoring podocyte integrity, implying that GW610742 may be a potential therapeutic agent for diabetic nephropathy."
3.	Mitochondrial Diseases (Mitochondrial Disease) 08/15/2007 - "GW610742 switched muscle fuel metabolism towards decreased carbohydrate use and enhanced lipid utilization, but did not induce mitochondrial dysfunction. "
4.	Muscular Atrophy (Muscle Atrophy) 08/15/2007 - "Furthermore, GW610742 initiated a muscle atrophy programme, possibly via changes in the Akt1/FOXO/MAFbx and MuRF1 signalling pathway."
5.	Infarction (Infarctions) 01/01/2016 - "GW610742 increased myofibroblast differentiation and transforming growth factor-beta 2 expression in the infarct zone at 7 days after MI. "

Related Drugs and Biologics

1.	Peroxisome Proliferator-Activated Receptors (PPAR)
2.	nephrin
3.	PPAR delta
4.	Transforming Growth Factor beta (TGF-beta)
5.	Lipids
6.	Desmin
7.	Carbohydrates